Therefore, the targeting of MDM2 by inhibitor Nutlin-3A re-established/upregulated FBXW7 in a p53-dependent manner and resulted in p63 degradation and thus made MAPKi-resistant melanoma cells susceptible to MAPKi treatment [78]. The gene discussed is TP53; the disease is melanoma.